Immunomedics is a clinical-stage biopharmaceutical company focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases. IMMU is developing multiple antibody-drug conjugate (ADC) products with its most promising candidate being IMMU-132. IMMU-132 is an ADC that contains SN-38, which is in clinical trials for the treatment of patients with metastatic triple-negative breast cancer (TNBC), and small-cell and non-small-cell lung cancers. IMMU-132 has been given Breakthrough Therapy designation by the FDA for the treatment of patients with TNBC who have failed prior therapies for metastatic disease.
IMMU is also developing a second ADC, known as IMMU-130, which is an anti-CEACAM5 antibody conjugated to SN-38. IMMU-130 is currently being studied in patients with metastatic colorectal cancer (mCRC) who have received at least one prior irinotecan-containing regimen and had an elevated blood titer of carcinoembryonic antigen.
Foresite Capital believes that IMMU-132 is a unique oncology asset and is likely to be approved for metastatic TNBC. IMMU-132 has produced compelling Phase 2 data including a response rate of 29%, progression-free survival of 6 months, and overall survival of 19 months. IMMU-132 has been granted Breakthrough Therapy designation based on the strength of these data.